Clinical Trials · NCT01174810
Exendin-4 as a Treatment for Parkinson's Disease - Pilot Study
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- University College, London
- Enrollment
- 40
- Start date
- Jul 2010
- Locations
- 1 site, United Kingdom
- Primary endpoint
- Change from baseline to 12 months & 14 months between patients on active Exenatide treatment and PD controls in respect of their UPDRS-off-medication motor subscore.